0001553878-18-000023.txt : 20180314
0001553878-18-000023.hdr.sgml : 20180314
20180314194023
ACCESSION NUMBER: 0001553878-18-000023
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180312
FILED AS OF DATE: 20180314
DATE AS OF CHANGE: 20180314
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KEATING LAURIE
CENTRAL INDEX KEY: 0001620743
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36407
FILM NUMBER: 18690708
MAIL ADDRESS:
STREET 1: 300 THIRD STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001178670
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770602661
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 THIRD STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 551-8200
MAIL ADDRESS:
STREET 1: 300 THIRD STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20020724
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2018-03-12
0
0001178670
ALNYLAM PHARMACEUTICALS, INC.
ALNY
0001620743
KEATING LAURIE
300 THIRD STREET
CAMBRIDGE
MA
02142
0
1
0
0
SVP, GC & Secretary
Common Stock
2018-03-12
4
M
0
10000
77.4
A
24500
D
Common Stock
2018-03-12
4
S
0
10000
140.0
D
14500
D
Common Stock
2018-03-13
4
M
0
10000
77.4
A
24500
D
Common Stock
2018-03-13
4
S
0
10000
150.0
D
14500
D
Common Stock
257
I
by Managed Account
Stock Option (right to buy)
77.4
2018-03-12
4
M
0
10000
0.0
D
2024-09-22
Common Stock
10000
82000
D
Stock Option (right to buy)
77.4
2018-03-13
4
M
0
10000
0.0
D
2024-09-22
Common Stock
10000
72000
D
All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017.
The reporting person owns 257 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.
By: /s/ Michael P. Mason, Attorney-in-Fact For: Laurie Keating
2018-03-14